About Abiomed

In November 2022, Abiomed announced that it entered into an Agreement and Plan of Merger with Johnson & Johnson. The transaction closed on December 22, 2022, and Abiomed is now a wholly-owned subsidiary of Johnson & Johnson. Please note, following the closing of the transaction, Abiomed was delisted from the NASDAQ exchange.

Abiomed is a leading provider of groundbreaking medical technology that provides circulatory and oxygenation support. The Impella® heart pump platform is designed to enable the heart to rest and recover by improving blood flow and/or temporarily assisting with the pumping function of the heart. The Abiomed Breethe OXY-1 System™ is designed to provide oxygenation while supporting patient mobility.

Financial and Operational Metrics

$1,032M

FY’22 Revenue​
15% 5-Year Revenue CAGR​

163M

Invested in R&D in FY’22
21% 5-year CAGR​

25%

FY’22 Non-GAAP OM​
15% 5-Year Non-GAAP OI CAGR​

979M

In Cash with $0 Debt

>1,400

Patents with more than
1,400 patents pending






Latest Press Releases

View All Press Releases

Featured Presentation

Latest Events

Latest Quarterly Reports

View All Quarterly Reports